Holen Sie sich die Stockscreener-App
1.775
4.57%
-0.085
Handel nachbörslich:
1.80
0.025
+1.41%
Schlusskurs vom Vortag:
$1.86
Offen:
$1.9
24-Stunden-Volumen:
10.53M
Relative Volume:
2.10
Marktkapitalisierung:
$292.72M
Einnahmen:
$101.21M
Nettoeinkommen (Verlust:
$-569.00K
KGV:
-88.75
EPS:
-0.02
Netto-Cashflow:
$-56.88M
1W Leistung:
-18.20%
1M Leistung:
-26.65%
6M Leistung:
+114.81%
1J Leistung:
+53.02%
1-Tages-Spanne:
$1.77
$2.08
1-Wochen-Bereich:
$1.77
$2.4275
52-Wochen-Spanne:
$0.40
$3.095
Cytomx Therapeutics Inc Stock (CTMX) Company Profile
Firmenname
Cytomx Therapeutics Inc
Sektor
Branche
Telefon
650.515.3185
Adresse
151 OYSTER POINT BLVD., SOUTH SAN FRANCISCO, CA
Vergleichen Sie CTMX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTMX
Cytomx Therapeutics Inc
|
1.775 | 306.74M | 101.21M | -569.00K | -56.88M | -0.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Cytomx Therapeutics Inc Stock (CTMX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-31 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2025-04-14 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-05-28 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-05-09 | Hochstufung | Wedbush | Neutral → Outperform |
| 2024-05-06 | Hochstufung | Jefferies | Hold → Buy |
| 2024-04-22 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2022-11-14 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-07-07 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-07 | Herabstufung | Mizuho | Buy → Neutral |
| 2022-07-07 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2022-06-24 | Eingeleitet | BMO Capital Markets | Outperform |
| 2022-01-18 | Hochstufung | Barclays | Underweight → Overweight |
| 2021-11-15 | Eingeleitet | BTIG Research | Buy |
| 2021-05-28 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2021-03-29 | Eingeleitet | JP Morgan | Overweight |
| 2021-03-23 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-22 | Herabstufung | Guggenheim | Buy → Neutral |
| 2020-06-01 | Herabstufung | Jefferies | Buy → Hold |
| 2020-05-14 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-24 | Hochstufung | Wedbush | Neutral → Outperform |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-20 | Eingeleitet | Guggenheim | Buy |
| 2019-11-11 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-06-13 | Eingeleitet | Mizuho | Buy |
| 2019-05-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-03-11 | Eingeleitet | Barclays | Overweight |
| 2018-11-26 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-10-15 | Eingeleitet | Goldman | Neutral |
| 2018-09-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-06-01 | Eingeleitet | SunTrust | Buy |
| 2018-01-05 | Eingeleitet | Citigroup | Buy |
| 2017-09-08 | Eingeleitet | Wedbush | Outperform |
| 2017-03-27 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-03-02 | Eingeleitet | Instinet | Buy |
| 2017-01-03 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2015-11-02 | Eingeleitet | Oppenheimer | Outperform |
Alle ansehen
Cytomx Therapeutics Inc Aktie (CTMX) Neueste Nachrichten
CytomX stock falls after reporting patient death in Phase 1 trial - Investing.com Canada
Declining Stock and Solid Fundamentals: Is The Market Wrong About CytomX Therapeutics, Inc. (NASDAQ:CTMX)? - 富途牛牛
CytomX Therapeutics Updates on CX-2051 Phase 1 Study - TipRanks
CytomX Therapeutics Provides Update on CX-2051 Phase 1 Study | C - GuruFocus
CytomX Therapeutics reports safety update in CX-2051 Phase 1 study - Investing.com Nigeria
CytomX Therapeutics provides update on CX-2051 Phase 1 study - MarketScreener
CytomX Cancer Drug Trial Continues Despite Patient Death, Phase 1 Data Expected Q1 2026 - Stock Titan
CytomX Therapeutics Earnings Call: Clinical Progress and Financial Strength - TipRanks
Published on: 2025-08-13 07:49:54 - 선데이타임즈
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Q2 2025 Earnings Call Transcript - Insider Monkey
CytomX Therapeutics Reports Strong Financial Turnaround - TipRanks
CytomX Therapeutics (CTMX.O) Surges 11.9% — What’s Behind the Unusual Move? - AInvest
CytomX Therapeutics Reports Improved Financials, Net Income Reaches $23.4 Million - AInvest
CytomX Therapeutics (CTMX): Navigating a Financial Downturn While Advancing Groundbreaking Cancer Therapies - AInvest
CytomX Therapeutics: Updated Outlook For Late 2025 (NASDAQ:CTMX) - Seeking Alpha
CytomX Therapeutics shares fall 2.51% after-hours following Q2 2025 earnings call. - AInvest
Transcript : CytomX Therapeutics, Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
Earnings call transcript: CytomX Q2 2025 results show revenue decline, stock dips - Investing.com
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
CytomX Therapeutics Inc (CTMX) Q2 2025 Earnings Call Highlights: Strategic Advances Amid Revenue Decline - GuruFocus
CytomX Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
CytomX Therapeutics Posts Q2 2025 Financials, Announces Positive CX-2051 Results, and Extends Runway to Q2 2027. - AInvest
CytomX Therapeutics Files $250M Mixed Securities Shelf for Future Fundraising - AInvest
CytomX Reports Q2 Revenue Drop of 26%, Narrows Operating Losses Amid Pipeline Progress - AInvest
CytomX (CTMX) Q2 Revenue Drops 26% - The Motley Fool
CytomX (CTMX) Q2 Revenue Drops 26% - Nasdaq
CytomX Therapeutics reports Q2 EPS 0c, consensus (6c) - TipRanks
CytomX Therapeutics (CTMX) Reports Break-Even Earnings for Q2 - Yahoo Finance
CytomX Therapeutics: Q2 Earnings Snapshot - San Antonio Express-News
CytomX Therapeutics Announces Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc Q2 2025 Earnings: EPS at $0.00 Beats Estimate, Revenue Surges to $18.7 Million - GuruFocus
CytomX Therapeutics files $250M mixed securities shelf - AInvest
CytomX Therapeutics Q2 Revenue Beats Estimates, Earnings Up 23.5M - AInvest
CytomX Therapeutics beats Q2 revenue estimates - MarketScreener
CytomX Earnings: Breakthrough Colorectal Cancer Drug Shows Promise as Company Raises $100M - Stock Titan
CytomX Therapeutics to Report Second Quarter 2025 Financial Resu - GuruFocus
CytomX Therapeutics Inc expected to post a loss of 8 cents a shareEarnings Preview - TradingView
Oppenheimer Initiates Coverage on CytomX Therapeutics (NASDAQ:CTMX) - MarketBeat
What are the technical indicators suggesting about CytomX Therapeutics Inc.Explosive earning power - Jammu Links News
Is CytomX Therapeutics Inc. a good long term investmentGame-changing returns - Jammu Links News
How volatile is CytomX Therapeutics Inc. stock compared to the marketGame-changing capital returns - Jammu Links News
CytomX Therapeutics (NASDAQ:CTMX) shareholders have earned a 79% return over the last year - Yahoo Finance
Why is CytomX Therapeutics Inc. stock attracting strong analyst attentionCapitalize on market trends with confidence - Jammu Links News
What institutional investors are buying CytomX Therapeutics Inc. stockCapitalize on fast-moving trading opportunities - Jammu Links News
What is the risk reward ratio of investing in CytomX Therapeutics Inc. stockCapitalize on market trends before they peak - Jammu Links News
Does CytomX Therapeutics Inc. stock perform well during market downturnsFree Capital Growth Strategies - Jammu Links News
What are analysts’ price targets for CytomX Therapeutics Inc. in the next 12 monthsInvest smarter with data-backed trading alerts - Jammu Links News
What are the latest earnings results for CytomX Therapeutics Inc.Overwhelming financial success - Jammu Links News
What is CytomX Therapeutics Inc. company’s growth strategyRapid capital growth - Jammu Links News
What makes CytomX Therapeutics Inc. stock price move sharplyFree Trading Psychology Coaching - Jammu Links News
How strong is CytomX Therapeutics Inc. company’s balance sheetMaximize returns with effective portfolio management - Jammu Links News
Finanzdaten der Cytomx Therapeutics Inc-Aktie (CTMX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):